Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity

Brain

Volumn 133, Issue 8, 2010, Pages 2232-2247

  Jones, Joanne L ^a   Anderson, Jane M ^a   Phuah, Chia Ling ^a   Fox, Edward J ^b   Selmaj, Krzysztof ^c   Margolin, David ^d   Lake, Stephen L ^d   Palmer, Jeffrey ^d   Thompson, Sara J ^a   Wilkins, Alastair ^a,e   Webber, Daniel J ^a   Compston, D Alastair ^a   Coles, Alasdair J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Central Texas Neurology Consultants   (United States)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d GENZYME CORPORATION   (United States)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Immunotherapy; Multiple sclerosis; Neurotrophins; Protective autoimmunity

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; MYELIN BASIC PROTEIN; NEUROTROPHIN; PLATELET DERIVED GROWTH FACTOR; BETA INTERFERON; CANCER ANTIBODY; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; SIGNAL PEPTIDE;

ADULT; ANIMAL CELL; ARTICLE; AUTOIMMUNITY; CELL CULTURE; CELL MATURATION; CELL SEPARATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; DISABILITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE; MALE; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; MYELINATION; NERVE CELL; NERVE ELONGATION; NERVE FIBER; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL; T LYMPHOCYTE; ANIMAL; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; DRUG EFFECTS; IMMUNOLOGY; IMMUNOMODULATION; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; AUTOIMMUNITY; CELLS, CULTURED; CROSS-SECTIONAL STUDIES; DISABILITY EVALUATION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERFERON-BETA; LONGITUDINAL STUDIES; LYMPHOCYTES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROIMMUNOMODULATION; RATS; RATS, SPRAGUE-DAWLEY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 77957044257     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awq176     Document Type: Article

References (49)

1. Abramoff M, Maglehaes P, Ram S. Image Processing with ImageJ. Biophotonics International 2004; 11: 36-42.
2. Aharoni R, Eilam R, Domev H, Labunskay G, Sela M, Arnon R. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci USA 2005; 102: 19045-19050
3. Aharoni R, Kayhan B, Eilam R, Sela M, Arnon R. Glatiramer acetatespecific T cells in the brain express T helper 2/3 cytokines and brainderived neurotrophic factor in situ. Proc Natl Acad Sci USA 2003; 100: 14157-14162
4. Azoulay D, Vachapova V, Shihman B, Miler A, Karni A. Lower brainderived neurotrophic factor in serum of relapsing remitting MS: Reversal by glatiramer acetate. J Neuroimmunol 2005; 167: 215-218
5. Barouch R, Schwartz M. Autoreactive T cells induce neurotrophin production by immune and neural cells in injured rat optic nerve: implications for protective autoimmunity. FASEB J 2002; 16: 1304-1306
6. Bieber AJ, Kerr S, Rodriguez M. Efficient central nervous system remyelination requires T cells. Ann Neurol 2003; 53: 680-684
7. Blanco Y, Moral EA, Costa M, Gomez-Choco M, Torres-Peraza JF, onso- Magdalena L, et al. Effect of glatiramer acetate (Copaxone(R)) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: A longitudinal study. Neuroscience Letters 2006; 406: 270-275
8. Coles A, Cox A, Le Page E, Jones J, Trip S, Deans J, et al. The window of therapeutic opportunity in multiple sclerosis. J Neurol 2006; 253: 98-108.
9. Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH,et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359: 1786-1801
10. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372: 1502-1517
11. Cox AL, Thompson SA, Jones JL, Robertson VH, Hale G, Waldmann H, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 2005; 35: 3332-3342
12. Grinspan JB, Reddy UR, Stern JL, Hardy M, Williams M, Baird L, et al. Oligodendroglia express PDGF beta-receptor protein and are stimulated to proliferate by PDGF. Ann NY Acad Sci 1990; 605: 71-80.
13. Hauben E, Butovsky O, Nevo U, Yoles E, Moalem G, Agranov E, et al. assive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. J Neurosci 2000a; 20: 6421-6430
14. Hauben E, Nevo U, Yoles E, Moalem G, Agranov E, Mor F, et al. Autoimmune T cells as potential neuroprotective therapy for spinal cord injury. Lancet 2000b; 355: 286-287
15. Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H. The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. J Neuroimmunol 2000; 107: 161-166
16. Hu Y, Turner MJ, Shields J, Gale MS, Hutto E, Roberts BL, et al. human CD52 transgenic mouse model. Immunology 2009; 128: 260-270
17. Johnson EW, Jones LA, Kozak RW. Expression and function of insulin-like growth factor receptors on anti-CD3-activated human T lymphocytes. J Immunol 1992; 148: 63-71.
18. Jones JL, Phuah CL, Cox AL, Thompson SA, Ban M, Shawcross J, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009; 119: 2052-2061
19. Jones TB, Ankeny DP, Guan Z, McGaughy V, Fisher LC, Basso DM, et al. Passive or active immunization with myelin basic protein impairs neurological function and exacerbates neuropathology after spinal cord injury in rats. J Neurosci 2004; 24: 3752-3761
20. Jones TB, Basso DM, Sodhi A, Pan JZ, Hart RP, MacCallum RC, et al. Pathological CNS autoimmune disease triggered by traumatic spinal cord injury: implications for autoimmune vaccine therapy. J Neurosci 2002; 22: 2690-2700
21. Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Misgeld T, Klinkert WEF, et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 1999; 189: 865-870
22. Kipnis J, Avidan H, Markovich Y, Mizrahi T, Hauben E, Prigozhina TB, et al. Low-dose gamma-irradiation promotes survival of injured neurons in the central nervous system via homeostasis-driven proliferation of T cells. Eur J Neurosci 2004; 19: 1191-1198
23. Kipnis J, Mizrahi T, Hauben E, Shaked I, Shevach E, Schwartz M. Neuroprotective autoimmunity: naturally occurring CD4+CD25+ regulatory T cells suppress the ability to withstand injury to the central nervous system. Proc Natl Acad Sci USA 2002a; 99: 15620-15625
24. Kipnis J, Mizrahi T, Yoles E, Ben-Nun A, Schwartz M. Myelin specific Th1 cells are necessary for post-traumatic protective autoimmunity. J Neuroimmunol 2002b; 130: 78-85.
25. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452
26. Mason JL, Suzuki K, Chaplin DD, Matsushima GK. Interleukin-1beta promotes repair of the CNS. J Neurosci 2001; 21: 7046-7052
27. McCarthy KD, deVellis J. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 1980; 85: 890-902.
28. McKinnon RD, Matsui T, Aranda M, Dubois-Dalcq M. A role for fibroblast growth factor in oligodendrocyte development. Ann N Y Acad Sci 1991; 638: 378-386
29. McKinnon RD, Matsui T, Dubois-Dalcq M, Aaronson SA. FGF modulates the PDGF-driven pathway of oligodendrocyte development. Neuron 1990; 5: 603-614
30. Moalem G, Gdalyahu A, Shani Y, Otten U, Lazarovici P, Cohen IR, et al. Production of neurotrophins by activated T cells: implications for neuroprotective autoimmunity. J Autoimmun 2000; 15: 331-345
31. Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, Schwartz M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 1999; 5: 49-55.
32. Moreau T, Coles A, Wing M, Isaacs J, Hale G, Waldmann H, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996; 119 (Pt 1): 225-237
33. Morell P, Barrett CV, Mason JL, Toews AD, Hostettler JD, Knapp GW, et al. Gene expression in brain during cuprizone-induced demyelination and remyelination. Mol Cell Neurosci 1998; 12: 220-227
34. Noble M, Murray K, Stroobant P, Waterfield MD, Riddle P. Plateletderived growth factor promotes division and motility and inhibits premature differentiation of the oligodendrocyte/type-2 astrocyte progenitor cell. Nature 1988; 333: 560-562
35. Oudega M, Xu XM, Guenard V, Kleitman N, Bunge MB. A combination of insulin-like growth factor-I and platelet-derived growth factor enhances myelination but diminishes axonal regeneration into Schwann cell grafts in the adult rat spinal cord. Glia 1997; 19: 247-258
36. Raff MC, Lillien LE, Richardson WD, Burne JF, Noble MD. Plateletderived growth factor from astrocytes drives the clock that times oligodendrocyte development in culture. Nature 1988; 333: 562-565
37. Redford EJ, Kapoor R, Smith KJ. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain 1997; 120 (Pt 12): 2149-2157
38. Scolding N, Franklin R, Stevens S, Heldin CH, Compston A, Newcombe J. Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis. Brain 1998; 121 (Pt 12): 2221-2228
39. Simpson PB, Armstrong RC. Intracellular signals and cytoskeletal elements involved in oligodendrocyte progenitor migration. Glia 1999; 26: 22-35.
40. Smith KJ, Kapoor R, Hall SM, Davies M. Electrically active axons degenerate when exposed to nitric oxide. Ann Neurol 2001; 49: 470-476
41. Stadelmann C, Kerschensteiner M, Misgeld T, Bruck W, Hohlfeld R, Lassmann H. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain 2002; 125: 75-85.
42. Thompson SA, Jones JL, Cox AL, Compston DA, Coles AJ. B-cell reconstitution and BAFF after alemtuzumab (campath-1H) treatment of multiple sclerosis. J Clin Immunol 2010; 30: 99-105.
43. Tu W, Cheung PT, Lau YL. IGF-I increases interferon-gamma and IL-6 mRNA expression and protein production in neonatal mononuclear cells. Pediatr Res 1999; 46: 748-754
44. Tu W, Cheung PT, Lau YL. Insulin-like growth factor 1 promotes cord blood T cell maturation and inhibits its spontaneous and phytohemagglutinin- induced apoptosis through different mechanisms. J Immunol 2000; 165: 1331-1336
45. Walsh PT, O'Connor R. The insulin-like growth factor-I receptor is regulated by CD28 and protects activated T cells from apoptosis. Eur J Immunol 2000; 30: 1010-1018
46. Walsh PT, Smith LM, O'Connor R. Insulin-like growth factor-1 activates Akt and Jun N-terminal kinases (JNKs) in promoting the survival of T lymphocytes. Immunology 2002; 107: 461-471
47. Wolswijk G, Noble M. Cooperation between PDGF and FGF converts slowly dividing O-2Aadult progenitor cells to rapidly dividing cells with characteristics of O-2Aperinatal progenitor cells. J Cell Biol 1992; 118: 889-900.
48. Wolswijk G. Oligodendrocyte precursor cells in the demyelinated multiple sclerosis spinal cord. Brain 2002; 125: 338-349
49. Zhao C, Li WW, Franklin RJ. Differences in the early inflammatory responses to toxin-induced demyelination are associated with the age-related decline in CNS remyelination. Neurobiol Aging 2006; 27: 1298-1307